-
OnKure Therapeutics, Inc. (OKUR) Misses Q4 EPS by 130c
-
Jones Trading Starts OnKure Therapeutics Inc. (OKUR) at Buy, PT $32
-
OnKure (OKUR) Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
-
Leerink Partners Starts OnKure Therapeutics Inc. (OKUR) at Outperform
-
Oppenheimer Starts OnKure Therapeutics Inc. (OKUR) at Outperform
-
OnKure Therapeutics (OKUR) Completes Merger with Reneo Pharmaceuticals, Concurrent $65M Private Placement

